Stocks In News (ONXX, ARO, ROST)
Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) soared 7.15% to $28.61. Late Wednesday, Onyx said it earned $42 million, or 66 cents a share, in the quarter, compared with $8 million or 14 cents a share, for the year-ago period. Revenue shot up to $123 million from $69 million, boosted by $59 million in license revenue derived from [...]
Stocks In News (ONXX, ARO, ROST)
Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) soared 7.15% to $28.61. Late Wednesday, Onyx said it earned $42 million, or 66 cents a share, in the quarter, compared with $8 million or 14 cents a share, for the year-ago period. Revenue shot up to $123 million from $69 million, boosted by $59 million in license revenue derived from [...]
US Stocks Alert (Genzyme Corporation, SCSC, ONXX, GILD)
Genzyme Corporation (NASDAQ:GENZ) slid 0.19% to $72.05. Earlier this month, Genzyme Corp.’s board unanimously rejected a $69-a-share offer for the company by Sanofi-Aventis SA, describing the offer as “inadequate and opportunistic.” Genzyme Corporation is a biotechnology company. The Company’s product and service portfolio is focused on rare genetic disease disorders, renal diseases, orthopaedics, cancer, transplant [...]
US Stocks to Watch (Genzyme Corporation, SCSC, ONXX, KLIC)
Genzyme Corporation (NASDAQ:GENZ) slid 0.46% to $72.10. Last week, Genzyme Corp.’s board unanimously rejected a $69-a-share offer for the company by Sanofi-Aventis SA, describing the offer as “inadequate and opportunistic.” Genzyme Corporation is a biotechnology company. The Company’s product and service portfolio is focused on rare genetic disease disorders, renal diseases, orthopaedics, cancer, transplant and [...]
Top Pre-Market Stock Losers (NMM, CYTX, ONXX)
Navios Maritime Partners L.P. (NYSE:NMM) fell 6.18% to $17.45 in pre market hours. The company plans to offer 5,500,000 common units representing limited partnership interests in a public offering. Navios Partners expects to grant the underwriters a 30-day option to purchase an additional 825,000 common units to cover over-allotments, if any. So far, the market [...]